GTバイオファーマ | 10-Q：Q3 2024 四半期報告書

SEC11/15 05:24

GT Biopharma: GTB-3650 TriKE Phase 1 Trial First Patient Dosed Expected in 4Q; Initial Clinical Data Expected in 2Q of 2025

Dow Jones11/15 05:11

GT Biopharma Reports Third Quarter 2024 Financial Results

GlobeNewswire11/15 05:00

GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GlobeNewswire09/26 21:15

GT Biopharma to Host Virtual KOL Event Showcasing Its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024

GlobeNewswire09/24 21:15

GT Biopharma GAAP EPS of -$2.17

Seeking Alpha08/15 19:44